Literature DB >> 22607078

Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever.

Hakan Leblebicioglu1, Hurrem Bodur, Basak Dokuzoguz, Nazif Elaldi, Rahmet Guner, Iftihar Koksal, Halil Kurt, Gonul Cicek Senturk.   

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne infection which has been increasing in Turkey and European countries since the year 2000. The disease is particularly endemic in the Middle East and in some African countries. It is also seen in European countries as a travel infection. Patients with confirmed diagnosis are usually hospitalized for monitoring, while patients with good overall condition may be monitored on an outpatient basis. Hospitals that manage CCHF should have easy access to a blood bank, and tertiary care hospitals must have a well-equipped intensive care unit. Strict blood and body fluid control precautions should be started on admission to limit CCHF exposure. The follow-up period for each patient is determined based on individual clinical status and laboratory values. Since there is no specific antiviral treatment for CCHF, supportive treatment is essential. This review highlights some of the major features of case monitoring and supportive treatment in CCHF.

Entities:  

Mesh:

Year:  2012        PMID: 22607078     DOI: 10.1089/vbz.2011.0896

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  20 in total

Review 1.  Recent advances in research on Crimean-Congo hemorrhagic fever.

Authors:  Anna Papa; Ali Mirazimi; Iftihar Köksal; Augustin Estrada-Pena; Heinz Feldmann
Journal:  J Clin Virol       Date:  2014-10-22       Impact factor: 3.168

2.  Understanding organ dysfunction in Ebola virus disease.

Authors:  Tom E Fletcher; Robert A Fowler; Nicholas J Beeching
Journal:  Intensive Care Med       Date:  2014-11-01       Impact factor: 17.440

Review 3.  Diagnostic Testing for Crimean-Congo Hemorrhagic Fever.

Authors:  Vanessa N Raabe
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

4.  Crimean-Congo hemorrhagic fever: Risk factors and control measures for the infection abatement.

Authors:  Saadia Aslam; Muhammad Shahzad Latif; Muhammad Daud; Zia Ur Rahman; Bushra Tabassum; Muhammad Sohail Riaz; Anwar Khan; Muhammad Tariq; Tayyab Husnain
Journal:  Biomed Rep       Date:  2015-11-18

Review 5.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

6.  Second International Conference on Crimean-Congo Hemorrhagic Fever.

Authors:  Jessica R Spengler; Dennis A Bente; Mike Bray; Felicity Burt; Roger Hewson; Gülay Korukluoglu; Ali Mirazimi; Friedemann Weber; Anna Papa
Journal:  Antiviral Res       Date:  2017-12-02       Impact factor: 5.970

7.  Direct healthcare costs for patients hospitalized with Crimean-Congo haemorrhagic fever can be predicted by a clinical illness severity scoring system.

Authors:  Ilkay Bozkurt; Mustafa Sunbul; Hava Yilmaz; Saban Esen; Hakan Leblebicioglu; Nicholas J Beeching
Journal:  Pathog Glob Health       Date:  2016-02-25       Impact factor: 2.894

Review 8.  The global distribution of Crimean-Congo hemorrhagic fever.

Authors:  Jane P Messina; David M Pigott; Nick Golding; Kirsten A Duda; John S Brownstein; Daniel J Weiss; Harry Gibson; Timothy P Robinson; Marius Gilbert; G R William Wint; Patricia A Nuttall; Peter W Gething; Monica F Myers; Dylan B George; Simon I Hay
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-07-04       Impact factor: 2.184

9.  Aetiology of PCR negative suspected Crimean-Congo hemorrhagic fever cases in an endemic area.

Authors:  Esra Tanyel; Mustafa Sunbul; Tom E Fletcher; Hakan Leblebicioglu
Journal:  Pathog Glob Health       Date:  2016 Jun-Jul       Impact factor: 2.894

10.  Infection prevention and control practice for Crimean-Congo hemorrhagic fever-A multi-center cross-sectional survey in Eurasia.

Authors:  Tom E Fletcher; Abuova Gulzhan; Salih Ahmeti; Seif S Al-Abri; Zahide Asik; Aynur Atilla; Nick J Beeching; Heval Bilek; Ilkay Bozkurt; Iva Christova; Fazilet Duygu; Saban Esen; Arjun Khanna; Çiğdem Kader; Masoud Mardani; Faisal Mahmood; Nana Mamuchishvili; Natalia Pshenichnaya; Mustafa Sunbul; Tuğba Y Yalcin; Hakan Leblebicioglu
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.